SIL204 treatment may help immune system attack KRAS-driven tumors, research finds - exclusive

Jerusalem Post

This comes just after SIL204 advanced into Phase 2/3 clinical evaluation at the end of July, beginning its first clinical trial at Tel Aviv Sourasky Medical Center.